Comparison between continuous or intermittent schedules of sublingual immunotherapy for house dust mites: Effects on compliance, patients' satisfaction, quality of life and safety

International Journal of Immunopathology and Pharmacology

Volumn 21, Issue 2, 2008, Pages 471-473

  Cadario, G ^a   Ciprandi, G ^b   Di Cara, G ^c   Fadel, R ^d   Incorvaia, C ^e   Marcucci, F ^c   Marengo, F ^a   Puccinelli, P ^f   Sensi, L ^c   Strazzeri, L ^g   Frati, Franco ^f,h  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c University Hospital   (Italy)

^d Stallergenes SA   (France)

^e ICP Hospital   (Italy)

^f Stallergenes   (Italy)

^g ASL   (Italy)

^h Medical and Scientific Department   (Italy)

Author keywords

Clinical efficacy; Compliance; Continuous schedule; Intermittent schedule; Mites; Safety; Sublingual immunotherapy

Indexed keywords

ALLERGEN; DERMATOPHAGOIDES FARINAE ALLERGEN; HOUSE DUST ALLERGEN; STALORAL 300;

ADOLESCENT; ADULT; ALLERGY; ARTICLE; CHILD; CLINICAL ARTICLE; CONJUNCTIVITIS; DERMATOPHAGOIDES; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MIXTURE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOTHERAPY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RHINITIS; SYMPTOMATOLOGY; TREATMENT RESPONSE;

EID: 47249134592     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200802100229     Document Type: Article

References (10)

1. Bousquet J, Lockey R, Mailing HJ. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998; 81:401-5.
2. Di Gioacchino M, Cavallucci E, Di Sciascio MB, Di Stefano F, Verna N, Raimondo S, Lobefalo L, Conti P, Cuccurullo F. Allergen immunotherapy: an effective immune-modifier. Int J Immunopathol Pharmacol 1999; 12:1-7.
3. Committee on safety in Medicine. Medicine CSM update: desensitizing vaccines. BMJ 1986; 293:948.
4. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol 2001; 108(suppl 5):147:5-11.
5. Madonini E, Agostini F, Barra R, Berra A, Donadio D, Stefani E, Pappacoda A, Tierno E. Safety and efficacy evaluation of sublingual allergen-specific immunotherapy: a retrospective, multicenter study. Int J Immunopathol Pharmacol 2000; 13:77-83.
6. Wilson DR, Torres-Lima M, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60:4-9.
7. Juniper EF. Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol 1997; 99:742-49.
8. Gidaro GB, Marcucci F, Sensi L, Incorvaia C, Frati F, Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 2005; 35:565-70.
9. Lombardi C, Gani F, Landi M, Falagiani P, Bruno M, Canonica GW, Passalacqua G. Quantitative assessment of the adherence to sublingual immunotherapy. J Allergy Clin Immunol 2004; 113: 1219-25.
10. Pajno GB, Vita D, Caminiti L, Arrigo T, Lombardo F, Incorvaia C, Barberio G. Children's compliance with allergen immunotherapy according to administration routes. J Allergy Clin Immunol 2005; 116:1380-86.